The ABSORB bioresorbable vascular scaffold: an evolution or revolution in interventional cardiology?

[1]  R. Whitbourn,et al.  Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial. , 2012, JACC. Cardiovascular interventions.

[2]  Patrick W Serruys,et al.  Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  Christodoulos I Stefanadis.  Stents for coronary artery disease: from covered to drug-eluting to bioabsorbable ... , 2012, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[4]  P. Serruys,et al.  3-Dimensional reconstruction of a bifurcation lesion with double wire after implantation of a second generation everolimus-eluting bioresorbable vascular scaffold. , 2011, International journal of cardiology.

[5]  P. Serruys,et al.  Three-dimensional reconstruction of the post-dilated ABSORB everolimus-eluting bioresorbable vascular scaffold in a true bifurcation lesion for flow restoration. , 2011, JACC. Cardiovascular interventions.

[6]  F. Eberli,et al.  Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial , 2011, Circulation.

[7]  R. Virmani,et al.  Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies , 2011, The International Journal of Cardiovascular Imaging.

[8]  Patrick W Serruys,et al.  Bioresorbable Scaffold: The Advent of a New Era in Percutaneous Coronary and Peripheral Revascularization? , 2011, Circulation.

[9]  Bernard Chevalier,et al.  Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. , 2011, Journal of the American College of Cardiology.

[10]  Bernard Chevalier,et al.  Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes , 2010, Circulation.

[11]  Bernard Chevalier,et al.  A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. , 2010, JACC. Cardiovascular interventions.

[12]  P. Serruys,et al.  Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[13]  Evelyn Regar,et al.  Cardiovascular flashlight. The fate of bioresorbable struts located at a side branch ostium: serial three-dimensional optical coherence tomography assessment. , 2010, European heart journal.

[14]  Patrick W Serruys,et al.  Coronary stents: looking forward. , 2010, Journal of the American College of Cardiology.

[15]  P. Serruys,et al.  Coronary stents: current status. , 2010, Journal of the American College of Cardiology.

[16]  P. Serruys,et al.  The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study. , 2010, European heart journal.

[17]  P. Serruys,et al.  IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus‐eluting device during the bioabsorption process , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[18]  B. Gersh,et al.  A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2010 .

[19]  A. Kastrati,et al.  Distribution of angiographic measures of restenosis after drug-eluting stent implantation , 2009, Heart.

[20]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.

[21]  Jan J Piek,et al.  A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. , 2005, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[22]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[23]  Jeffrey J. Popma,et al.  Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2001, Circulation.

[24]  S. Parikh,et al.  Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. , 2001, Circulation.

[25]  A. Colombo,et al.  Edge Restenosis After Implantation of High Activity 32P Radioactive β-Emitting Stents , 2000 .

[26]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[27]  A Gruntzig,et al.  Transluminal dilatation of coronary-artery stenosis. , 1978, Lancet.